A detailed history of Caxton Corp transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Caxton Corp holds 5,113,348 shares of XERS stock, worth $15.8 Million. This represents 62.59% of its overall portfolio holdings.

Number of Shares
5,113,348
Previous 5,113,348 -0.0%
Holding current value
$15.8 Million
Previous $11.5 Million 26.67%
% of portfolio
62.59%
Previous 61.49%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$2.04 - $3.22 $1.08 Million - $1.7 Million
-528,572 Reduced 9.37%
5,113,348 $11.3 Million
Q2 2023

Aug 14, 2023

SELL
$1.82 - $2.98 $722,736 - $1.18 Million
-397,108 Reduced 6.58%
5,641,920 $14.8 Million
Q1 2022

May 16, 2022

SELL
$2.0 - $2.87 $543,036 - $779,256
-271,518 Reduced 4.3%
6,039,028 $15.5 Million
Q4 2021

Feb 14, 2022

BUY
$1.8 - $2.93 $11.4 Million - $18.5 Million
6,310,546 New
6,310,546 $18.5 Million

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $420M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Caxton Corp Portfolio

Follow Caxton Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caxton Corp, based on Form 13F filings with the SEC.

News

Stay updated on Caxton Corp with notifications on news.